

IAP04Rec'd PCT 20 AUG 2008 PCT

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: August 18th 2008

By:

Mari Kleineidam
Mari Kleineidam



PATENT

Attorney Docket No. GC819-2-US/B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	Group Art Unit: 1632
)	
Jones, Brian E. et al.)	Examiner: Not yet assigned
)	
Serial No.: 10/576,331)	Confirmation No.: 7214
)	
Filed: July 18, 2007)	
)	
For: SERINE PROTEASES, NUCLEIC)	
ACIDS ENCODING SERINE ENZYMES)	
AND VECTORS AND HOST CELLS)	
INCORPORATING SAME)	

TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed are the following documents:

1. Information Disclosure Statement (3 page(s), in duplicate);
2. Form PTO-1449 (7 page(s)); and
3. Copies of ~~101~~ references, and International Search Report in corresponding PCT Application No. PCT/US2004/039066.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required, or credit any overpayment to Deposit Account No. 07-1048, referencing Attorney Docket No. GC819-2-US/B. A duplicate of this paper is enclosed.

Respectfully submitted,

Dated: 12 August 2008

Kamrin T. MacKnight
Kamrin T. MacKnight
Reg. No. 38,230

Danisco US Inc., Genencor Division
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel.: (650) 846-5838
Fax: (650) 845-6504

GC819-2-US/B T-IDS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: August 12, 2008

By: Mari Kleineidam

Mari Kleineidam



PATENT

Attorney Docket No. GC819-2-US/B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	Group Art Unit: 1632
)	
Jones, Brian E. et al.)	Examiner: Not yet assigned
)	
Serial No.: 10/576,331)	Confirmation No.: 7214
)	
Filed: July 18, 2007)	
)	
For: SERINE PROTEASES, NUCLEIC)	
ACIDS ENCODING SERINE ENZYMES)	
AND VECTORS AND HOST CELLS)	
INCORPORATING SAME)	

TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed are the following documents:

1. Information Disclosure Statement (3 page(s), in duplicate);
2. Form PTO-1449 (7 page(s)); and
3. Copies of references and International Search Report in corresponding PCT Application No. PCT/US2004/039066.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required, or credit any overpayment to Deposit Account No. 07-1048, referencing Attorney Docket No. GC819-2-US/B. A duplicate of this paper is enclosed.

Respectfully submitted,

Dated: 12 August 2008

Kamrin T. MacKnight
Kamrin T. MacKnight
Reg. No. 38,230

Danisco US Inc., Genencor Division
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel.: (650) 846-5838
Fax: (650) 845-6504

GC819-2-US/B T-IDS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: August 18, 2008

By:

Mari Kleineidam
Mari Kleineidam

PATENT

Attorney Docket No. GC819-2-US/B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	Confirmation No.: 7214
Jones, Brian E. et al.)	
)	Group Art Unit: 1632
Serial No.: 10/576,331)	
)	Examiner: Not yet assigned
Filed: July 18, 2007)	
)	
For: SERINE PROTEASES, NUCLEIC)	
ACIDS ENCODING SERINE)	
ENZYMES AND VECTORS AND)	
HOST CELLS INCORPORATING)	
SAME)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

(a) ☐ accompanies the new patent application submitted herewith. 37 CFR §1.97(a).

(b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.

(c) ☒ as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.

(d) ☐ is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.

(e) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(l)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.**

[If either of boxes (d) or (e) is checked above, the following "certification" under 37 CFR §1.97(e) must be completed.] The undersigned certifies that:

☐ Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application and to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

A copy of the items on Form PTO-1449 is supplied: PCT International Search Report for PCT/US2004/039066, mailed September 5, 2005 with attached patents and publications.

☒ each ☐ none ☐ only those listed below:

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s)

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Dated: 12 August 2008


Kamrin T. MacKnight
Reg. No. 38,230

Danisco US, Inc., Genencor Division
925 Page Mill Road
Palo Alto, CA 94304-1013
Phone: (650) 846-5838
Fax: (650) 845-6504

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: August 12, 2008

By: Mari Kleineidam

Mari Kleineidam

PATENT

Attorney Docket No. GC819-2-US/B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Jones, Brian E. et al.

Serial No.: 10/576,331

Filed: July 18, 2007

For: SERINE PROTEASES, NUCLEIC
ACIDS ENCODING SERINE
ENZYMES AND VECTORS AND
HOST CELLS INCORPORATING
SAME

Confirmation No.: 7214

Group Art Unit: 1632

Examiner: Not yet assigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

(a) ☐ accompanies the new patent application submitted herewith. 37 CFR §1.97(a).

(b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.

(c) ☒ as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.



The PTO did not receive the following
listed item(s) Form PTO-1449
(4 sheets)

(d) ☐ is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.

(e) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(l)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.**

[If either of boxes (d) or (e) is checked above, the following "certification" under 37 CFR §1.97(e) must be completed.] The undersigned certifies that:

☐ Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application and to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

A copy of the items on Form PTO-1449 is supplied: PCT International Search Report for PCT/US2004/039066, mailed September 5, 2005 with attached patents and publications.

☒ each ☐ none ☐ only those listed below:

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s)

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Dated: 12 August 2008


Kamrin T. MacKnight
Reg. No. 38,230

Danisco US, Inc., Genencor Division
925 Page Mill Road
Palo Alto, CA 94304-1013
Phone: (650) 846-5838
Fax: (650) 845-6504